国际肿瘤学杂志

国际肿瘤学杂志 ›› 2012, Vol. 39 ›› Issue (12): 907-909.

• 综述 • 上一篇    下一篇

洛铂治疗肿瘤的研究进展

孙娜, 杨文燕   

  1. 250062 济南，山东省医学科学院医药卫生科技信息研究所 山东省医学科学院
  • 出版日期:2012-12-08 发布日期:2012-11-15

Progression of lobaplatin for cancer

SUN  Na, YANG  Wen-Yan   

  1. Shandong Institute of Medicine and Health Information, Shandong Academy of Medical Sciences, Jinan 250062, China
  • Online:2012-12-08 Published:2012-11-15

PDF

1791

被引次数

2

摘要： 洛铂是第3代铂类抗肿瘤药物。大量临床前药效学研究显示，洛铂能阻断细胞周期的运行，诱导细胞凋亡，从而有效抑制肿瘤细胞增殖，且与顺铂无交叉耐药性。洛铂对多种肿瘤患者亦有较好的疗效，且不良反应轻微，安全性较好。

关键词: 肿瘤, 药效学, 临床研究, 洛铂

Abstract: Lobaplatin isthe third generation platinum drug.Many studies on pharmacodynamics have been confirmed that lobaplatin can block the cell cycle and induce cell apoptosis, and thus inhibits tumor cell proliferation effectively. Lobaplatinis not cross-resistant to cisplatin. Besides, it has good curative effect to various kinds of cancer patients with mild adverse reactions, and the patients are well tolerable to it.

Key words: Neoplasms, font-size: 12pt, mso-font-kerning: 1.0pt, mso-ansi-language: EN-US, mso-fareast-language: ZH-CN, mso-bidi-language: AR-SA, mso-bidi-font-family: 'Times New Roman', mso-bidi-font-size: 14.0pt" lang="EN-US">Pharmacodynamics, font-size: 12pt, mso-font-kerning: 1.0pt, mso-ansi-language: EN-US, mso-fareast-language: ZH-CN, mso-bidi-language: AR-SA, mso-bidi-font-family: 'Times New Roman', mso-bidi-font-size: 14.0pt" lang="EN-US">Clinical research, font-size: 12pt, mso-font-kerning: 1.0pt, mso-ansi-language: EN-US, mso-fareast-language: ZH-CN, mso-bidi-language: AR-SA, mso-bidi-font-family: 'Times New Roman', mso-bidi-font-size: 14.0pt" lang="EN-US">Lobaplatin